Lianyungang, China

Mengxue Fan

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):

Title: Mengxue Fan: Innovator in Pharmaceutical Composition for Tumor Treatment

Introduction

Mengxue Fan is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of biomedicine, particularly in the development of pharmaceutical compositions aimed at treating various types of tumors. His innovative work has the potential to impact cancer treatment positively.

Latest Patents

Mengxue Fan holds a patent for a combined pharmaceutical composition for treating tumors. This composition is specifically designed for biliary tract tumors, liver cancer, triple-negative breast cancer, and lung cancer. The formulation includes an anti-PD-L1 antibody and anlotinib, demonstrating effective anti-cancer activity against these malignancies. He has 1 patent to his name.

Career Highlights

Throughout his career, Mengxue Fan has worked with prominent companies in the pharmaceutical industry. He has been associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Nanjing Shunxin Pharmaceuticals Co., Ltd., both of which are part of the Chiatai Tianqing Pharmaceutical Group. His experience in these organizations has contributed to his expertise in drug development.

Collaborations

Mengxue Fan has collaborated with notable colleagues in his field, including Xiquan Zhang and Xunqiang Wang. These partnerships have likely enhanced his research and development efforts in creating effective cancer treatments.

Conclusion

Mengxue Fan's contributions to the field of biomedicine, particularly in cancer treatment, highlight his role as an innovative inventor. His work continues to pave the way for advancements in pharmaceutical compositions aimed at combating various tumors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…